Citi analyst Yigal Nochomovitz lowered the price target on Ovid Therapeutics Inc (NASDAQ: OVID) to $1.20 (from $3.50) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE